Sickle Cell Scholar Component

镰状细胞学者组件

• 批准号: 8263399
• 负责人: Victor R Gordeuk
• 金额: $ 9.74万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8263399
• 关键词: Area; Biochemical Genetics; Biochemistry; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Design; Data; Databases; Development; Development Plans; Discipline; Disease; Doctor of Philosophy; Educational Curriculum; Ensure; Epidemiology; Faculty; Functional disorder; Future; Genetic; Genomics; Goals; Healthcare; Immunogenetics; Institutional National Research Service Award; Investigation; Joints; Laboratories; Lead; Leadership; Learning; Mentored Clinical Scientist Development Program; Mentors; Mentorship; Molecular Biology; Molecular Genetics; NCI Scholars Program; Physicians; Research; Research Ethics; Research Personnel; Research Project Grants; Research Training; Scientist; Sickle Cell; Sickle Cell Anemia; Stigmata; Structure; Techniques; Training; Training Programs; Translational Research; United States National Institutes of Health; Universities; Vascular Diseases; Washington; Work; burden of illness; care delivery; career; career development; design; improved; innovation; interest; iron metabolism; multidisciplinary; programs; skills; social stigma; statistics; success; tool

The Scholar will spend at least 75 percent of his/her effort in sickle cell anemia-related research under the leadership of Dr. Luban, an established clinical investigator who also directs faculty training and mentorship at CNMC. Dr. Luban in conjunction with the physicians and scientist of WACSCC will develop a carefully planned, individualized research training program designed to ensure that the Scholar becomes an independent physician and/or biomedical researcher focused on critical translational and clinical questions related to sickle cell disease. An individualized career development plan (ICDP) (Appendix A) will be developed for the Sickle Cell Scholar and will encompass three major components: core curriculum, laboratory training and translational applications in the clinical setting. The first component is formal course work including a variety of disciplines: statistics, epidemiology, clinical trial design, regulatory aspects of clinical investigation, research ethics, scientific tools of clinical investigation, analytical techniques in clinical investigation, and principles and techniques of biochemistry, molecular biology and molecular genetics. These courses will be provided through the HU (RR010284) and CNMC (RR020359) Clinical Research Centers and the HU Research Scientist Program (R25HL003679) augmented by our joint K30 and associated T32 and K12 programs and by course work at HUSM and CNMC, local universities and through selected programs at NIH The second component provides a highly structured laboratory training program that is designed to provide practical training in biochemistry, molecular biology, genetics and analytic techniques, and in the analysis of clinical and laboratory data that results from bench investigations and clinical investigation implemented at the WACSCC collaborative laboratories and GCRCs. Physician scientists and epidemiologic researchers with interests in health care disparities and care delivery will engage in programs designed to learn methodological approaches to data- based investigations and quantitative research. The third component consists of developing and conducting a clinical project in sickle cell disease. The scholar will design, implement and participate in the conduct of a mentored clinical research project. This part of Scholar's training will ensure that he/she develops the training needed to conduct multidisciplinary clinical research, recognize the difficulties in such studies and develop tools to ensure future success as a clinical researcher or collaborative biomedical researcher. The ultimate goal of the Sickle Cell Scholar program is to inspire young and/or new investigators to devote their career to innovative and productive research that will lead to decreasing the disease burden and stigmata of this disease.

学者将在 Luban 博士的领导下将至少 75% 的精力用于镰状细胞性贫血相关研究。Luban 博士是一位资深的临床研究人员，同时还指导 CNMC 的教师培训和指导。 Luban 博士将与 WACSCC 的医生和科学家一起制定一项精心策划的个性化研究培训计划，旨在确保学者成为一名独立的医生和/或生物医学研究员，专注于与镰状细胞病相关的关键转化和临床问题。将为镰状细胞学者制定个性化职业发展计划 (ICDP)（附录 A），该计划将包括三个主要组成部分：核心课程、实验室培训和临床环境中的转化应用。 第一部分是正式课程，包括各种学科：统计学、流行病学、临床试验设计、临床研究的监管方面、研究伦理、临床研究的科学工具、临床研究的分析技术以及生物化学、分子生物学的原理和技术 和分子遗传学。这些课程将通过 HU (RR010284) 和 CNMC (RR020359) 临床研究中心以及 HU 研究科学家计划 (R25HL003679) 提供，并由我们联合加强 K30 和相关的 T32 和 K12 课程以及 HUSM 和 CNMC、当地大学的课程作业以及 NIH 的选定课程 第二部分提供高度结构化的实验室培训计划，旨在提供生物化学、分子生物学、遗传学和分析技术方面的实践培训，以及对 WACSCC 合作实验室和 GCRC 实施的实验室调查和临床调查产生的临床和实验室数据分析的实践培训。医师科学家和流行病学 对医疗保健差异和医疗服务提供感兴趣的研究人员将参与旨在学习基于数据的调查和定量研究的方法学方法的项目。 第三部分包括开发和开展镰状细胞病临床项目。 学者将设计、实施和参与指导的临床研究项目。这部分学者培训将确保他/她接受进行多学科临床研究所需的培训，认识到此类研究中的困难，并开发工具以确保未来作为临床研究员或合作生物医学研究员取得成功。 镰状细胞学者计划的最终目标是激励年轻和/或新的研究人员将他们的职业生涯奉献给创新和富有成效的研究，从而减少这种疾病的疾病负担和耻辱。